Harrow Health, Inc. (HROW)
USD 23.83
(4.02%)
USD 23.83
(4.02%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -24.41 Million USD | -73.3% |
| 2022 | -14.08 Million USD | 21.77% |
| 2021 | -18 Million USD | -426.67% |
| 2020 | -3.41 Million USD | -31.91% |
| 2019 | -2.59 Million USD | -117.72% |
| 2018 | 14.62 Million USD | 222.03% |
| 2017 | -11.98 Million USD | 37.21% |
| 2016 | -19.08 Million USD | -20.05% |
| 2015 | -15.89 Million USD | -57.13% |
| 2014 | -10.11 Million USD | -32.38% |
| 2013 | -7.64 Million USD | -41.97% |
| 2012 | -5.38 Million USD | -464.35% |
| 2011 | -953.93 Thousand USD | 62.31% |
| 2010 | -2.53 Million USD | 44.41% |
| 2009 | -4.55 Million USD | -37.81% |
| 2008 | -3.3 Million USD | 22.88% |
| 2007 | -4.28 Million USD | -9172.69% |
| 2006 | -46.2 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -6.47 Million USD | 52.28% |
| 2024 Q1 | -13.56 Million USD | -48.28% |
| 2023 Q2 | -4.22 Million USD | 36.34% |
| 2023 Q1 | -6.64 Million USD | -729.67% |
| 2023 Q3 | -4.39 Million USD | -3.83% |
| 2023 FY | -24.41 Million USD | -73.3% |
| 2023 Q4 | -9.14 Million USD | -108.34% |
| 2022 Q1 | -2.29 Million USD | 69.01% |
| 2022 FY | -14.08 Million USD | 21.77% |
| 2022 Q4 | 1.05 Million USD | 116.32% |
| 2022 Q3 | -6.46 Million USD | -3.61% |
| 2022 Q2 | -6.23 Million USD | -171.38% |
| 2021 Q3 | -8.32 Million USD | -236.08% |
| 2021 FY | -18 Million USD | -426.67% |
| 2021 Q1 | 217 Thousand USD | -81.11% |
| 2021 Q2 | -2.47 Million USD | -1241.94% |
| 2021 Q4 | -7.41 Million USD | 10.93% |
| 2020 Q1 | -12.9 Million USD | -585.77% |
| 2020 Q3 | 8.63 Million USD | 3744.73% |
| 2020 FY | -3.41 Million USD | -31.91% |
| 2020 Q2 | -237 Thousand USD | 98.16% |
| 2020 Q4 | 1.14 Million USD | -86.7% |
| 2019 FY | -2.59 Million USD | -117.72% |
| 2019 Q1 | 11.35 Million USD | -37.35% |
| 2019 Q2 | -2.37 Million USD | -120.94% |
| 2019 Q3 | -11.46 Million USD | -382.3% |
| 2019 Q4 | 2.65 Million USD | 123.17% |
| 2018 Q2 | 2.52 Million USD | 171.79% |
| 2018 Q3 | -2.51 Million USD | -199.68% |
| 2018 Q4 | 18.13 Million USD | 821.16% |
| 2018 Q1 | -3.51 Million USD | -26.78% |
| 2018 FY | 14.62 Million USD | 222.03% |
| 2017 Q4 | -2.77 Million USD | 51.32% |
| 2017 Q3 | -5.69 Million USD | -483.56% |
| 2017 Q2 | 1.48 Million USD | 129.64% |
| 2017 FY | -11.98 Million USD | 37.21% |
| 2017 Q1 | -5 Million USD | 17.96% |
| 2016 Q4 | -6.1 Million USD | -58.49% |
| 2016 Q2 | -4.63 Million USD | -3.18% |
| 2016 Q3 | -3.85 Million USD | 17.01% |
| 2016 FY | -19.08 Million USD | -20.05% |
| 2016 Q1 | -4.49 Million USD | 12.26% |
| 2015 Q3 | -3.95 Million USD | -5.95% |
| 2015 Q4 | -5.12 Million USD | -29.66% |
| 2015 FY | -15.89 Million USD | -57.13% |
| 2015 Q1 | -3.09 Million USD | -12.67% |
| 2015 Q2 | -3.73 Million USD | -20.59% |
| 2014 Q2 | -2.59 Million USD | -11.64% |
| 2014 FY | -10.11 Million USD | -32.38% |
| 2014 Q4 | -2.74 Million USD | -11.96% |
| 2014 Q3 | -2.45 Million USD | 5.54% |
| 2014 Q1 | -2.32 Million USD | -23.54% |
| 2013 Q4 | -1.88 Million USD | 9.4% |
| 2013 FY | -7.64 Million USD | -41.97% |
| 2013 Q1 | -1.46 Million USD | -0.86% |
| 2013 Q2 | -2.21 Million USD | -51.35% |
| 2013 Q3 | -2.07 Million USD | 6.34% |
| 2012 Q3 | -1.24 Million USD | 4.58% |
| 2012 Q2 | -1.3 Million USD | 5.33% |
| 2012 FY | -5.38 Million USD | -464.35% |
| 2012 Q1 | -1.37 Million USD | -407.47% |
| 2012 Q4 | -1.45 Million USD | -16.63% |
| 2011 Q2 | -164.46 Thousand USD | 61.96% |
| 2011 Q1 | -432.31 Thousand USD | -1.45% |
| 2011 Q3 | -85.4 Thousand USD | 48.07% |
| 2011 Q4 | -271.75 Thousand USD | -218.22% |
| 2011 FY | -953.93 Thousand USD | 62.31% |
| 2010 FY | -2.53 Million USD | 44.41% |
| 2010 Q3 | -746.46 Thousand USD | -52.96% |
| 2010 Q2 | -488 Thousand USD | 43.95% |
| 2010 Q1 | -870.61 Thousand USD | -12.19% |
| 2010 Q4 | -426.15 Thousand USD | 42.91% |
| 2009 FY | -4.55 Million USD | -37.81% |
| 2009 Q1 | -1.62 Million USD | -70.05% |
| 2009 Q4 | -776.02 Thousand USD | 16.41% |
| 2009 Q3 | -928.34 Thousand USD | 24.4% |
| 2009 Q2 | -1.22 Million USD | 24.25% |
| 2008 Q4 | -953.39 Thousand USD | -16.99% |
| 2008 Q1 | -272.72 Thousand USD | 82.06% |
| 2008 FY | -3.3 Million USD | 22.88% |
| 2008 Q3 | -814.95 Thousand USD | 35.49% |
| 2008 Q2 | -1.26 Million USD | -363.23% |
| 2007 FY | -4.28 Million USD | -9172.69% |
| 2007 Q2 | -1109.00 USD | 41.54% |
| 2007 Q3 | -2.5 Million USD | -226145.63% |
| 2007 Q4 | -1.51 Million USD | 39.43% |
| 2007 Q1 | -1897.00 USD | 34.65% |
| 2006 Q4 | -2903.00 USD | 62.46% |
| 2006 FY | -46.2 Thousand USD | 0.0% |
| 2006 Q3 | -7733.00 USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Aquestive Therapeutics, Inc. | -7.87 Million USD | -210.178% |
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 150.693% |
| Journey Medical Corporation | -3.85 Million USD | -533.558% |
| Dynavax Technologies Corporation | -6.38 Million USD | -282.079% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 88.334% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 82.523% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 158.184% |
| PainReform Ltd. | -9.34 Million USD | -161.248% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | -199.038% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -441.739% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -441.739% |
| SCYNEXIS, Inc. | 67.04 Million USD | 136.412% |
| Silver Spike Investment Corp. | 7.34 Million USD | 432.57% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -687.825% |
| Alpha Teknova, Inc. | -36.78 Million USD | 33.63% |
| Alvotech | -551.73 Million USD | 95.576% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 229.991% |
| Bright Green Corporation | -13.12 Million USD | -85.951% |
| Embecta Corp. | 70.4 Million USD | 134.675% |
| Safety Shot Inc | -15.08 Million USD | -61.844% |
| Procaps Group, S.A. | 42.54 Million USD | 157.384% |
| Cosmos Health Inc. | -18.54 Million USD | -31.648% |
| Theratechnologies Inc. | -23.95 Million USD | -1.895% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -404.881% |
| Biofrontera Inc. | -20.13 Million USD | -21.261% |
| DURECT Corporation | -27.62 Million USD | 11.631% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 1954.939% |
| Cronos Group Inc. | -73.96 Million USD | 66.996% |
| OptiNose, Inc. | -35.48 Million USD | 31.204% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 97.564% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 42.153% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 202.07% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 593.65% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | 15546.774% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | -288.752% |
| Radius Health, Inc. | -25.79 Million USD | 5.351% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -296.086% |
| ProPhase Labs, Inc. | -16.78 Million USD | -45.459% |
| Phibro Animal Health Corporation | 2.41 Million USD | 1110.389% |
| Procaps Group S.A. | 42.54 Million USD | 157.384% |
| TherapeuticsMD, Inc. | -10.27 Million USD | -137.507% |
| Viatris Inc. | 54.7 Million USD | 144.627% |
| Rockwell Medical, Inc. | -8.43 Million USD | -189.264% |
| Aytu BioPharma, Inc. | -15.84 Million USD | -54.071% |
| SIGA Technologies, Inc. | 68.06 Million USD | 135.862% |
| Tilray Brands, Inc. | -244.98 Million USD | 90.036% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 303.205% |
| Shineco, Inc. | -22.44 Million USD | -8.74% |
| PetIQ, Inc. | 2.13 Million USD | 1245.519% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -467.455% |
| Incannex Healthcare Limited | -18.45 Million USD | -32.244% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 109.776% |
| Alimera Sciences, Inc. | -20.13 Million USD | -21.255% |
| Assertio Holdings, Inc. | -331.94 Million USD | 92.646% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | -270.272% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | -36.382% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -21.706% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 84.769% |
| Hempacco Co., Inc. | -13.12 Million USD | -85.973% |
| Talphera, Inc. | -18.39 Million USD | -32.69% |
| Alvotech | -551.73 Million USD | 95.576% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | 168.489% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 107.473% |
| Currenc Group, Inc. | -15.3 Million USD | -59.481% |
| Kamada Ltd. | 8.28 Million USD | 394.676% |
| Indivior PLC | 2 Million USD | 1320.55% |
| Evoke Pharma, Inc. | -7.79 Million USD | -213.271% |
| Flora Growth Corp. | -57.03 Million USD | 57.201% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -21.706% |
| Evolus, Inc. | -61.68 Million USD | 60.426% |
| HUTCHMED (China) Limited | 100.78 Million USD | 124.222% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 117.748% |
| Akanda Corp. | -32.27 Million USD | 24.366% |